Galmed Pharmaceuticals (GLMD) Enterprise Value (2013 - 2025)

Galmed Pharmaceuticals' Enterprise Value history runs 13 years deep, the most recent figure standing at -$4.1 million for Q4 2025.

• In Q4 2025, Enterprise Value rose 49.57% year-over-year to -$4.1 million; the TTM figure through Dec 2025 stood at -$4.1 million (up 49.57% YoY), while the FY2025 annual figure was -$4.1 million, up 49.57% from the prior year.
• Enterprise Value was -$4.1 million for Q4 2025 at Galmed Pharmaceuticals, down from -$1.7 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $2.2 million in Q2 2023 to a low of -$34.8 million in Q4 2021.
• Historically, Enterprise Value has averaged -$5.5 million across 5 years, with a median of -$3.7 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value jumped 200.05% in 2023, then sank 893.33% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$34.8 million in 2021, then surged by 93.88% to -$2.1 million in 2022, then plunged by 140.09% to -$5.1 million in 2023, then slumped by 59.33% to -$8.1 million in 2024, then soared by 49.57% to -$4.1 million in 2025.
• The last three Enterprise Value figures came in at -$4.1 million (Q4 2025), -$1.7 million (Q3 2025), and -$3.3 million (Q2 2025), per Business Quant data.